PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) dropped 3.3% during mid-day trading on Thursday . The stock traded as low as $0.7006 and last traded at $0.7266. Approximately 86,486 shares were traded during trading, an increase of 879% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7512.
PharmaCyte Biotech Stock Performance
The company’s fifty day moving average is $0.74 and its 200-day moving average is $0.77.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Featured Articles
- Five stocks we like better than PharmaCyte Biotech
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
